<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767767</url>
  </required_header>
  <id_info>
    <org_study_id>0710009434</org_study_id>
    <secondary_id>K08GM083213</secondary_id>
    <nct_id>NCT00767767</nct_id>
  </id_info>
  <brief_title>The Effect of Intravenous Anesthetics on Fear Learning and Memory</brief_title>
  <official_title>The Effect of Intravenous Anesthetics on Fear Learning and Memory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People often develop fearful responses to things, but have no conscious control over the
      fear. This is a basic form of unconscious memory, called &quot;fear conditioning.&quot; Intravenous
      anesthetic drugs have remarkable effects on conscious memory, but it is unknown whether they
      have similar effects on these unconscious fear memories.

      To address this question, the investigators will study 114 healthy adult volunteer subjects.
      The subject is given a very low dose of an anesthetic drug intravenously (i.e. through the
      bloodstream). The dose is so low that the subject might not even be able tell if they are
      getting the drug. While they are receiving the drug, the subject will perform a series of
      memory tests and a fear conditioning experiment, which are set up like a very simple computer
      game. To create the &quot;fear response&quot;, subjects will occasionally receive a mildly
      uncomfortable shock to their arm. The subject is able to determine the highest level of shock
      that they will receive.

      The investigators are doing this study because the investigators wish to know exactly how the
      drugs affect the way people process fear and emotion. This knowledge might one day be used in
      the treatment of some psychiatric disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People often develop fearful responses to things, but have no conscious control over the fear
      (e.g. phobias). This is a basic form of unconscious memory, called &quot;fear conditioning.&quot;
      Intravenous anesthetic drugs have remarkable effects on conscious memory, but it is unknown
      whether they have similar effects on these unconscious fear memories.

      To address this question, the investigators will study 114 healthy adult volunteer subjects.
      The subject is given a very low dose of an anesthetic drug intravenously (i.e. through the
      bloodstream). The dose is so low that the subject might not even be able tell if they are
      getting the drug. While they are receiving the drug, the subject will perform a series of
      memory tests and a fear conditioning experiment, which are set up like a very simple computer
      game. To create the &quot;fear response&quot;, subjects will occasionally receive a mildly
      uncomfortable shock to their arm. The subject is able to determine the highest level of shock
      that they will receive.

      The investigators are doing this study because the investigators wish to know exactly how the
      drugs affect the way people process fear and emotion. This knowledge might one day be used in
      the treatment of some psychiatric disorders.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GSR Trial 1</measure>
    <time_frame>First Trial, for up to 1 day</time_frame>
    <description>Galvanic skin repose (GSR) to the first habituation trial (yes/no). Coding: Yes (0) and No (1)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Phobias</condition>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 0.45mcg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthetic Drug Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 0.90mcg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthetic Drug Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thiopental 1.5mcg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthetic Drug Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thiopental 3mcg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthetic Drug Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>IV Saline infusion for 2 hours.</description>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 0.45mcg/mL</intervention_name>
    <description>IV Propofol infusion for 2 hours.</description>
    <arm_group_label>Propofol 0.45mcg/mL</arm_group_label>
    <other_name>Propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 0.90mcg/mL</intervention_name>
    <description>IV Propofol infusion for 2 hours.</description>
    <arm_group_label>Propofol 0.90mcg/mL</arm_group_label>
    <other_name>Propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiopental 1.5mcg/mL</intervention_name>
    <description>IV Thiopental 1.5mcg/mL infusion for 2 hours</description>
    <arm_group_label>Thiopental 1.5mcg/mL</arm_group_label>
    <other_name>Thiopental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiopental 3mcg/mL</intervention_name>
    <description>IV Thiopental 3mcg/mL infusion for 2 hours</description>
    <arm_group_label>Thiopental 3mcg/mL</arm_group_label>
    <other_name>Thiopental</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 50

          -  minimum of high school education

          -  fluent in English

          -  normal vocabulary

        Exclusion Criteria:

          -  any significant medical or psychiatric comorbidity (e.g. asthma, diabetes,
             hypertension, depression, high anxiety)--subjects must be in excellent health such
             that they would be classified as American Society of Anesthesiologists Physical Status
             Class I

          -  deficit in vision or hearing that would impede the study

          -  allergies to any of the study drugs, to soybeans, or to eggs

          -  a history of head trauma

          -  a family history of major psychiatric illness

          -  body mass index &gt; 30 kg/m2

          -  a recent history of recreational drug use

          -  prior exposure to the study materials

          -  pregnancy

          -  a personal or family history of any porphyria

          -  failure to exhibit a skin conductance response to deep inspiration

          -  the ability to read Chinese characters

          -  assessment by the investigators that the subject may be unable to cooperate or comply
             with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kane Pryor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <results_first_submitted>February 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anesthetic drugs, associative memory, fear</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Thiopental</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebos</title>
          <description>Saline Infusion
Placebos: IV Saline infusion for 2 hours.</description>
        </group>
        <group group_id="P2">
          <title>Propofol 0.45mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.45mcg/mL: IV Propofol infusion for 2 hours.</description>
        </group>
        <group group_id="P3">
          <title>Propofol 0.9mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.9mcg/mL: IV Propofol infusion for 2 hours.</description>
        </group>
        <group group_id="P4">
          <title>Thiopental 1.5mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 1.5mcg/mL: IV Thiopental infusion for 2 hours.</description>
        </group>
        <group group_id="P5">
          <title>Thiopental 3mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 3mcg/mL: IV Thiopental Infusion for 2 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebos</title>
          <description>Saline Infusion
Placebos: IV Saline infusion for 2 hours.</description>
        </group>
        <group group_id="B2">
          <title>Propofol 0.45mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.45mcg/mL: IV Propofol infusion for 2 hours.</description>
        </group>
        <group group_id="B3">
          <title>Propofol 0.9mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.9mcg/mL: IV Propfol infusion for 2 hours.</description>
        </group>
        <group group_id="B4">
          <title>Thiopental 1.5mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 1.5mcg/mL: IV Thiopental infusion for 2 hours.</description>
        </group>
        <group group_id="B5">
          <title>Thiopental 3mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 3mcg/mL: IV Thiopental Infusion for 2 hours.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="4.4"/>
                    <measurement group_id="B2" value="25.4" spread="4.1"/>
                    <measurement group_id="B3" value="25.6" spread="4.5"/>
                    <measurement group_id="B4" value="23.7" spread="3.4"/>
                    <measurement group_id="B5" value="26.3" spread="5.8"/>
                    <measurement group_id="B6" value="25.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GSR Trial 1</title>
        <description>Galvanic skin repose (GSR) to the first habituation trial (yes/no). Coding: Yes (0) and No (1)</description>
        <time_frame>First Trial, for up to 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebos</title>
            <description>Saline Infusion
Placebos: IV Saline infusion for 2 hours.</description>
          </group>
          <group group_id="O2">
            <title>Propofol 0.45mcg/mL</title>
            <description>Anesthetic Drug Infusion
Propofol 0.45mcg/mL: IV Propofol infusion for 2 hours.</description>
          </group>
          <group group_id="O3">
            <title>Propofol 0.9mcg/mL</title>
            <description>Anesthetic Drug Infusion
Propofol 0.9mcg/mL: IV Propfol infusion for 2 hours.</description>
          </group>
          <group group_id="O4">
            <title>Thiopental 1.5mcg/mL</title>
            <description>Anesthetic Drug Infusion
Thiopental 1.5mcg/mL: IV Thiopental infusion for 2 hours.</description>
          </group>
          <group group_id="O5">
            <title>Thiopental 3mcg/mL</title>
            <description>Anesthetic Drug Infusion
Thiopental 3mcg/mL: IV Thiopental Infusion for 2 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>GSR Trial 1</title>
          <description>Galvanic skin repose (GSR) to the first habituation trial (yes/no). Coding: Yes (0) and No (1)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".62" spread=".50"/>
                    <measurement group_id="O2" value=".55" spread=".51"/>
                    <measurement group_id="O3" value=".55" spread=".51"/>
                    <measurement group_id="O4" value=".67" spread=".5"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebos</title>
          <description>Saline Infusion
Placebos: IV Saline infusion for 2 hours.</description>
        </group>
        <group group_id="E2">
          <title>Propofol 0.45mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.45mcg/mL: IV Propofol infusion for 2 hours.</description>
        </group>
        <group group_id="E3">
          <title>Propofol 0.90mcg/mL</title>
          <description>Anesthetic Drug Infusion
Propofol 0.90mcg/mL: IV Propofol infusion for 2 hours.</description>
        </group>
        <group group_id="E4">
          <title>Thiopental 1.5mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 1.5mcg/mL: IV Thiopental 1.5mcg/mL infusion for 2 hours</description>
        </group>
        <group group_id="E5">
          <title>Thiopental 3mcg/mL</title>
          <description>Anesthetic Drug Infusion
Thiopental 3mcg/mL: IV Thiopental 3mcg/mL infusion for 2 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Extreme Fidgety</sub_title>
                <description>Extremely fidgety, dosing on and off, requiring prompting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kane Pryor</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>(212) 746-2969</phone>
      <email>kap9009@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

